SEC Comment Letter 0000000000-25-001476 to CDT Equity Inc. (CDT)
CDT Equity Inc.
Date: Feb. 11, 2025 · CIK: 0001896212 · Accession: 0000000000-25-001476
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-284714
Letter
February 11, 2025 David Tapolczay, Ph.D. Chief Executive Officer Conduit Pharmaceuticals Inc. 4581 Tamiami Trail North, Suite 200 Naples, Florida 34103 Re:Conduit Pharmaceuticals Inc. Registration Statement on Form S-3 Filed February 5, 2025 File No. 333-284714 Dear David Tapolczay Ph.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Todd Mason, Esq.
Show Raw Text
February 11, 2025
David Tapolczay, Ph.D.
Chief Executive Officer
Conduit Pharmaceuticals Inc.
4581 Tamiami Trail North, Suite 200
Naples, Florida 34103
Re:Conduit Pharmaceuticals Inc.
Registration Statement on Form S-3
Filed February 5, 2025
File No. 333-284714
Dear David Tapolczay Ph.D.:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Todd Mason, Esq.